Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators,...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

HoldenMeown Jul. 2 at 8:54 PM

$CTMX This was a good week.

1 · Reply

lidopete Jul. 2 at 4:46 PM

$CTMX - POSITIVE- AI assist- The recent underwhelming CDH17 benchmark from Multitude Therapeutics highlights the competitive edge for differentiated targets like EpCAM, where CTMX has shown encouraging activity and disease control rates of ~84-90% in a heavily pretreated population. The underwhelming CDH17 benchmark from Multitude highlights the competitive edge for differentiated targets like EpCAM, where CTMX has shown encouraging activity and disease control rates of ~84-90% in a heavily pretreated population. This positions CTMX favorably for dose optimization readouts in H2 2026 and potential registrational advancement in 4th-line+ CRC, as their data exceeds recent cross-trial comparators in the ADC field.

0 · Reply

bryantboy99 Jun. 30 at 11:11 PM

$CTMX lots of volume at the close again today.

0 · Reply

Turdsniffer Jun. 30 at 5:11 PM

$CTMX yes daddy, yes

0 · Reply

prismmarketview Jun. 30 at 3:50 PM

Better men's health begins with partners in care. This Men's Health Month, PRISM MarketView is highlighting the companies whose innovation is extending lifespans across the lifespan — from mental health to cardiovascular care to oncology. Mental Health & Access: Late-stage psychiatric therapeutics from $DFTX + DTC men's wellness scale via $HIMS Cardiovascular Innovation: Inflammatory heart disease pipeline at $CRDL + nanosecond pulsed field ablation for AF at $PLSE Precision Oncology: First-in-class EpCAM ADC for colorectal cancer from $CTMX Read our full analysis: https://prismmarketview.com/partners-in-care-how-modern-medicine-is-closing-the-gap-on-mens-health/ #MensHealthMonth #MentalHealth #Cardiology #Oncology #MarketInsights #PRISMMarketView

0 · Reply

AnomalyDetective Jun. 30 at 1:56 PM

💥$ACHV biotech the first of the new Week 27 MDA picks for members to gain 10% extending the count of at least one pick gaining over 10% in less than a week to 373 weeks. 💥 Biotech breakout with $LABU $XBI $SBIO in the most positive Healthcare sector gauge signal leading all sectors for June. 💥 Many prior MDA biotech stocks back in breakout conditions like$FATE $SANA $CTMX follow the signals for the best results. Free prior selections: http://top.vmbreakouts.com Credit: http://vmbreakouts.com @vmbreakouts

1 · Reply

dheim Jun. 30 at 12:56 AM

$CTMX every 10 cents is 5k. Can’t wait till this is 50

3 · Reply

bryantboy99 Jun. 30 at 12:51 AM

$CTMX big block trade at the close.

0 · Reply

HoldenMeown Jun. 29 at 6:43 PM

$CTMX It’s not FOMO for Shorts. They literally have cover the shares they’ve BORROWED as the share price increases. If you buy shares and the price goes down, you can only lose the money you’ve invested. There’s no limit as to how much a Short buyer can lose. It’s whatever the price is to return their borrowed shares.

0 · Reply

TonyPhils Jun. 29 at 6:27 PM

$CTMX keep chasing it, fomo please short seller. it the bait to let you your share cheaply at 3 and now have to chase it to 4

0 · Reply

CytomX Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 3:10 PM EDT - 4 weeks ago

CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T13:28:50.000Z - 4 weeks ago

CytomX Therapeutics expands licensing agreement with Regeneron

REGN

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

May 21, 2026, 8:00 AM EDT - 6 weeks ago

CytomX Therapeutics to Present at Upcoming June Investor Conferences

2026-05-19T10:13:05.000Z - 6 weeks ago

CytomX Therapeutics initiated with an Outperform at Wolfe Research

May 18, 2026, 8:00 AM EDT - 6 weeks ago

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

2026-05-11T10:24:04.000Z - 7 weeks ago

CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright

2026-05-07T22:15:03.000Z - 2 months ago

CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)

May 7, 2026, 5:00 PM EDT - 2 months ago

CytomX Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

CytomX Therapeutics Quarterly report: Q1 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

CytomX Therapeutics Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

CytomX Therapeutics Slides: Q1 2026

May 7, 2026, 4:15 PM EDT - 2 months ago

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

Apr 30, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Proxy statement: Proxy filing

2026-04-13T14:25:10.000Z - 2 months ago

CytomX Therapeutics participates in a conference call with JPMorgan

2026-03-23T10:55:06.000Z - 3 months ago

CytomX Therapeutics price target raised to $12 from $10 at Piper Sandler

2026-03-19T09:25:41.000Z - 3 months ago

CytomX Therapeutics price target raised to $16 from $10 at Barclays

2026-03-18T14:25:35.000Z - 3 months ago

CytomX Therapeutics price target raised to $16 from $8 at Jefferies

2026-03-18T11:05:22.000Z - 3 months ago

CytomX Therapeutics price target raised to $15 from $10 at Guggenheim

2026-03-18T10:12:07.000Z - 3 months ago

CytomX Therapeutics 45.9M share Secondary priced at $5.30

Mar 17, 2026, 10:46 PM EDT - 3 months ago

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

2026-03-17T11:56:10.000Z - 3 months ago

CytomX Therapeutics price target raised to $11 from $6 at Wedbush

2026-03-16T20:10:52.000Z - 3 months ago

CytomX Therapeutics announces $250M common stock offering

2026-03-16T20:05:42.000Z - 3 months ago

CytomX Therapeutics files automatic mixed securities shelf

Mar 16, 2026, 4:04 PM EDT - 3 months ago

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-03-16T16:05:23.000Z - 3 months ago